A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
The Albany facility is the company's main research and development site in the industry, and has recently partnered with Seattle-based technology company EnerG2 to produce carbon electrode material, in a 74,000-square-foot (6,900 m2) former distribution center of Oregon Freeze Dry by 2011 bringing a new green technology industry to Albany. Tec Laboratories has made Tecnu poison ivy cleanser and other topical medicines in Albany since 1977. Albany is also home to the Albany Research Center, which is part of National Energy Technology Laboratory (NETL). They employ a staff of 120. Albany Research Center was founded in 1943, the laboratory specializes in life cycle research starting with the formulation, characterization, and/or melting of most metals, alloys, and ceramics; casting and fabrication, prototype development; and the recycle and remediation of waste streams associated with these processes. The Heritage Mall, an enclosed shopping center, opened on November 2, 1988. The construction of a regional shopping center had been planned for a decade and included proposals to build a rival mall in Corvallis.
Alan Dershowitz, Claus's attorney, wrote a book about the case, Reversal of Fortune: Inside the von Bülow Case (New York, Random House 1986 and London, Penguin Books 1991). The 1990 film Reversal of Fortune was based on Dershowitz's books about the case, with Glenn Close playing Sunny and Jeremy Irons playing Claus von Bülow, a performance for which he was awarded an Academy Award for Best Actor. Bill Kurtis narrated an episode of the series American Justice titled "Von Bulow: A Wealth of Evidence". The American television series Biography produced and aired a documentary episode titled "Claus von Bülow: A Reasonable Doubt", with interviews of Claus Von Bülow and Alan Dershowitz. The case is referenced in the Seinfeld episode "The Suicide". Jerry Seinfeld is in a hospital room watching over a comatose neighbor. To the neighbor's ex-girlfriend he remarked, "It's not like a Sunny Von Bülow coma. Doctor said he should snap out of it anytime." Sunny is referenced in the American television show Will & Grace, in which socialite Karen Walker asks more than once about Sunny being “out of bed.”
This is an important consideration because cholesterol—the precursor to all steroid hormones—does not leave the membrane once it has embedded itself inside. The difference between cholesterol and these hormones is that cholesterol is in a much larger negative Gibb's free energy well once inside the membrane, as compared to these hormones. This is because the aliphatic tail on cholesterol has a very favorable interaction with the interior of lipid bilayers.
The soybean oil emulsion does not harm normal human cells, or the cells of most other higher organisms, with the exceptions of sperm cells and blood cells, which are vulnerable to nanoemulsions due to the peculiarities of their membrane structures. For this reason, these nanoemulsions are not used intravenously (IV). The most effective application of this type of nanoemulsion is for the disinfecting of surfaces. Some types of nanoemulsion have been shown to effectively destroy HIV-1 and tuberculosis pathogens on non-porous surfaces.
Sources: en.wikipedia.org
Although indirect conflict between Cold War powers continued through the late 1960s and early 1970s, tensions were beginning to ease. Following the ousting of Khrushchev, another period of collective leadership ensued, consisting of Leonid Brezhnev as general secretary, Alexei Kosygin as Premier and Nikolai Podgorny as Chairman of the Presidium, lasting until Brezhnev established himself in the early 1970s as the preeminent Soviet leader. Following his visit to China, Nixon met with Soviet leaders in Moscow. These Strategic Arms Limitation Talks resulted in landmark arms control treaties. These aimed to limit the development of costly anti-ballistic missiles and nuclear missiles. Nixon and Brezhnev proclaimed a new era of "peaceful coexistence" and established the groundbreaking new policy of détente (or cooperation) between the superpowers. Meanwhile, Brezhnev attempted to revive the Soviet economy, which was declining in part because of heavy military expenditures. The Soviet Union's military budget in the 1970s was massive, 40–60% of the federal budget and 15% of GDP. Between 1972 and 1974, the two sides also agreed to strengthen their economic ties, including agreements for increased trade. As a result of their meetings, détente would replace the hostility of the Cold War and the two countries would live mutually. These developments coincided with Bonn's Ostpolitik policy formulated by the West German Chancellor Willy Brandt, an effort to normalize relations between West Germany and Eastern Europe.
== Monitoring == Mold spores are always present in the environment and when conditions are favorable, mold will occur. Regular monitoring of the collection through visual inspection and environmental controls is essential to prevent an outbreak. Mold leaves a visual indication of its presence. Though mold can be any color, gray and black spots coupled with a musty odor can indicate the presence of mold. Books with these indicators can be isolated and treatment steps can be implemented. Books in the surrounding area can be monitored in case of further infestation. Presence of water or condensation and dust are other factors to look out for that can encourage mold growth. Regular cleaning and inspections will help monitor for mold growth. The control and regular monitoring of temperature and humidity levels is vital to prevent mold growth. Guidelines suggest that temperatures be maintained between 65–70 °F (18–21 °C) and relative humidity between 45%-65%. HVAC systems can be utilized and monitored to ensure these levels are maintained. Temperature and humidity values can be systematically measured and recorded to document conditions, to alert of severe fluctuations, and to indicate the functionality of the climate control systems. The systems themselves should be regularly checked for accuracy and functionality.
The uses of ayahuasca in traditional societies in South America vary greatly. Some cultures do use it for shamanic purposes, but in other cases, it is consumed socially among friends, in order to learn more about the natural environment. Nonetheless, people who work with ayahuasca in non-traditional contexts often align themselves with the philosophies and cosmologies associated with ayahuasca shamanism, as practiced among Indigenous peoples like the Urarina of the Peruvian Amazon. Dietary taboos are often associated with the use of ayahuasca, although these seem to be specific to the culture around Iquitos, Peru, a major center of ayahuasca tourism. Ayahuasca retreats or healing centers can also be found in the Sacred Valley of Peru, in areas such as Cusco and Urubamba, where similar dietary preparations can be observed. These retreats often employ members of the Shipibo-Konibo tribe, an indigenous community native to the Peruvian Amazon. In the rainforest, these taboos tend towards the purification of one's self—abstaining from spicy and heavily seasoned foods, excess fat, salt, caffeine, acidic foods (such as citrus) and sex before, after, or during a ceremony. A diet low in foods containing tyramine has been recommended, as the speculative interaction of tyramine and MAOIs could lead to a hypertensive crisis; however, evidence indicates that harmala alkaloids act only on MAO-A, in a reversible way similar to moclobemide (an antidepressant that does not require dietary restrictions).
=== Effects in males === LH acts upon the Leydig cells of the testis and is regulated by gonadotropin-releasing hormone (GnRH). The Leydig cells produce testosterone under the control of LH. LH binds to LH receptors on the membrane surface of Leydig cells. Binding to this receptor causes an increase in cyclic adenosine monophosphate (cAMP), a secondary messenger, which allows cholesterol to translocate into the mitochondria. Within the mitochondria, cholesterol is converted to pregnenolone by CYP11A1. Pregnenolone is then converted to dehydroepiandrosterone (DHEA). DHEA is then converted to androstenedione by 3β-hydroxysteroid dehydrogenase (3β-HSD) and then finally converted to testosterone by 17β-hydroxysteroid dehydrogenase (HSD17B). The onset of puberty is controlled by two major hormones: FSH initiates spermatogenesis and LH signals the release of testosterone, an androgen that exerts both endocrine activity and intratesticular activity on spermatogenesis. LH is released from the pituitary gland, and is controlled by pulses of gonadotropin-releasing hormone. When bloodstream testosterone levels are low, the pituitary gland is stimulated to release LH. As the levels of testosterone increase, it will act on the pituitary through a negative feedback loop and inhibit the release of GnRH and LH consequently. Androgens (including testosterone and dihydrotestosterone) inhibit monoamine oxidase (MAO) in the pineal gland, leading to increased melatonin and reduced LH and FSH by melatonin-induced increase of gonadotropin-inhibitory hormone (GnIH) synthesis and secretion.
Mephedrone and the cathinones marked somewhat of a turning point for designer drugs, turning them from little known, ineffective substances sold in head shops to powerful substances able to compete with classical drugs on the black market. Mephedrone especially experienced a somewhat meteoric rise in popularity in 2009 and the resulting media panic resulted in its prohibition in multiple countries. Following this there was a considerable emergence of other cathinones which attempted to mimic the effects of mephedrone, and with a newly attracted customer base, plenty of money to drive innovation. Subsequently, the market rapidly expanded, with more and more substances being detected every year. In 2009, the EMCDDA's early warning system discovered 24 new drugs. In 2010, it found another 41; in 2011, another 49; and in 2012, there were 73 more. In 2013, a further 81 were identified: a total of 268 new drugs in just four years. These have not been limited to cathinones, with 35% being cannabinoids and the rest being composed of stimulants, benzodiazepines, psychedelics, dissociatives and to a lesser extent, every other class of drugs, even ibogoids and nootropics. The largest group of drugs being monitored by the EMCDDA is synthetic cannabinoids, with 209 different synthetic cannabinoids reported between 2008 and 2021 - including 11 new cannabinoids identified for the first time in 2020.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.